Sulfaguanidine (Guanicil), a sulfonamide, is served as an anti-infective agent.

Adult rats exhibit a more robust elimination capability for Sulfaguanidine when compared to neonatal rats. Pharmacokinetic studies of gastrointestinal absorption reveal that, following oral administration, the peak plasma concentration in adult rats is significantly lower than that in neonatal rats, although there is no marked difference in the time taken to reach peak blood levels. The absolute bioavailability in adult rats (12.76%) is approximately one-fifth that of neonatal rats (57.86%). In adults, the plasma elimination of Sulfaguanidine, administered intravenously at doses of 2.5 or 25 mg/kg, can be described by a two-compartment open model. Conversely, the plasma concentration profile of Sulfaguanidine, post oral administration of 25 mg/kg, is consistent with a one- or two-compartment open model. Consequently, Sulfaguanidine is less readily absorbed in adult rats, while neonatal rats demonstrate effective absorption.

Sulfaguanidine, one of the earliest sulfa drugs employed in the treatment of intestinal infections, effectively inhibits the synthesis of nutritional factors in intestinal bacteria. It also efficiently impedes the growth of Gram-negative enterobacteria.